| John A. Collier,, D.d.s., P.a. | |
|
2162 S Lamar Blvd Oxford MS 38655-5224 | |
| (662) 236-1969 | |
| (662) 513-5878 |
| Full Name | John A. Collier,, D.d.s., P.a. |
|---|---|
| Speciality | Dentist |
| Location | 2162 S Lamar Blvd, Oxford, Mississippi |
| Authorized Official Name and Position | John Alex Collier (OWNER) |
| Authorized Official Contact | 6622361969 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| John A. Collier,, D.d.s., P.a. 2162 S Lamar Blvd Oxford MS 38655-5224 Ph: (662) 236-1969 | John A. Collier,, D.d.s., P.a. 2162 S Lamar Blvd Oxford MS 38655-5224 Ph: (662) 236-1969 |
| NPI Number | 1477825636 |
|---|---|
| Provider Enumeration Date | 02/03/2012 |
| Last Update Date | 02/03/2012 |
| Medicare PECOS PAC ID | 5092029314 |
|---|---|
| Medicare Enrollment ID | O20150730013471 |
News Archive
Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.
A team of scientists from the UC San Diego School of Medicine and Osaka University in Japan have identified a protein switch that helps prevent liver damage, including inflammation, fibrosis and cancer. The findings suggest that a better understanding of how the protein, TAK1, works could lead to new insights into the development of liver disease and cancer.
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
To date, there have been relatively few cases of neonates with COVID-19, and there is limited knowledge of neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, recent studies have suggested an increased risk of severe COVID-19 in infants compared to older children, which is based on data that shows an increased rate of hospitalization among infants.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477825636 | NPI | - | NPPES |
| 00660152 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 2869-95 (Mississippi) | Primary |
| Provider Name | John Collier |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1376672618 PECOS PAC ID: 5890009617 Enrollment ID: I20150806011250 |
News Archive
Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.
A team of scientists from the UC San Diego School of Medicine and Osaka University in Japan have identified a protein switch that helps prevent liver damage, including inflammation, fibrosis and cancer. The findings suggest that a better understanding of how the protein, TAK1, works could lead to new insights into the development of liver disease and cancer.
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
To date, there have been relatively few cases of neonates with COVID-19, and there is limited knowledge of neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, recent studies have suggested an increased risk of severe COVID-19 in infants compared to older children, which is based on data that shows an increased rate of hospitalization among infants.
› Verified 1 days ago
News Archive
Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.
A team of scientists from the UC San Diego School of Medicine and Osaka University in Japan have identified a protein switch that helps prevent liver damage, including inflammation, fibrosis and cancer. The findings suggest that a better understanding of how the protein, TAK1, works could lead to new insights into the development of liver disease and cancer.
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
To date, there have been relatively few cases of neonates with COVID-19, and there is limited knowledge of neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, recent studies have suggested an increased risk of severe COVID-19 in infants compared to older children, which is based on data that shows an increased rate of hospitalization among infants.
› Verified 1 days ago
Oxford Dental Clinic Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2155 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-5222 Fax: 662-234-5254 | |
Life Dental Oxford Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2608 S Lamar Blvd, Oxford, MS 38655 Phone: 662-281-8455 Fax: 815-461-8253 | |
Ross Family Dental Clinic Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 127 Heritage Dr, Oxford, MS 38655 Phone: 662-234-2722 | |
Go Orthodontics Partnership Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2408 S Lamar Blvd, Suite 2, Oxford, MS 38655 Phone: 662-234-4822 Fax: 662-234-9032 | |
Oxford Family Dental Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2162 S Lamar Blvd, Oxford, MS 38655 Phone: 662-236-1969 | |
Abraham Dental Oxford Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2156 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-4504 Fax: 662-510-0545 |